Cannot Therapeutics, Inc.

Suman Atwal

Daniel A Erlanson

Stig Hansen

Raymond V Fucini

Shyam Krishnan

Steven Sethofer

Andrew Sawayama

Johan Enquist

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor ('GLP?1R') and/or the gastric inhibitory polypeptide receptor ('GIPR'). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple)-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

Modulators of G-protein coupled receptors

Growing community of inventors

San Jose, CA, United States of America

Suman Atwal